Adagene Inc
ADAG
查看詳細走勢圖
1.820USD
-0.010-0.55%
收盤 12/19, 16:00（美東）報價延遲15分鐘
107.22M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-0.55%
5天
+4.00%
1月
+1.11%
6月
-4.21%
今年開始到現在
-8.54%
1年
-11.22%
查看詳細走勢圖
TradingKey Adagene Inc股票評分
單位: USD 更新時間: 2025-10-27操作建議
當前估值低估，機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Adagene Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
8
分析師
買入
評級
9.224
目標均價
+363.53%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Adagene Inc亮點
亮點風險
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
業績增長期
公司處於發展階段，最新年度總收入103.20K美元
估值合理
公司最新PE估值-3.59，處於3年歷史合理位
機構減倉
最新機構持股14.91M股，環比減少11.08%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉0.00股
活躍度增加
近期活躍度增加，過去20天平均換手率0.90
Adagene Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Adagene Inc簡介
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
公司代碼ADAG
公司Adagene Inc
CEOLuo (Peter)
網址https://www.adagene.com/
常見問題
Adagene Inc(ADAG)的當前股價是多少？
Adagene Inc(ADAG)的當前股價是 1.820。
Adagene Inc 的股票代碼是什麼？
Adagene Inc的股票代碼是ADAG。
Adagene Inc股票的52週最高點是多少？
Adagene Inc股票的52週最高點是3.160。
Adagene Inc股票的52週最低點是多少？
Adagene Inc股票的52週最低點是1.300。
Adagene Inc的市值是多少？
Adagene Inc的市值是107.22M。
Adagene Inc的淨利潤是多少？
Adagene Inc的淨利潤為-33.42M。
現在Adagene Inc(ADAG)的股票是買入、持有還是賣出？
根據分析師評級，Adagene Inc(ADAG)的總體評級為買入，目標價格為9.224。
Adagene Inc(ADAG)股票的每股收益（EPS TTM）是多少
Adagene Inc(ADAG)股票的每股收益（EPS TTM）是-0.515。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
